Immunic Strengthens Board of Directors with Elena Ridloff Appointment
Immunic, Inc., a biotechnology firm that specializes in developing innovative oral therapies aimed at addressing neurologic diseases, has announced a significant addition to its Board of Directors: the appointment of Elena Ridloff, CFA. Starting from August 6, 2026, this strategic move is expected to bolster the company’s financial and operational leadership, particularly as Immunic readies itself for pivotal progress in its clinical programs.
Michael W. Bonney, the Chair of Immunic's Board, expressed enthusiasm over this new appointment. 'We are excited to welcome Elena to our Board as we enter an important period for Immunic,' he stated. He emphasized Ridloff’s extensive experience and reputation within the biotech sector, believing her insights will prove invaluable as the company navigates its next chapter.
Mr. Erik Lundgren, CEO of Immunic, added that the company is approaching critical milestones, such as the anticipated top-line data from the Phase 3 ENSURE trials involving vidofludimus calcium, intended for the treatment of relapsing multiple sclerosis (MS). He noted that this period marks a crucial phase in the company’s growth trajectory. With Ridloff's impressive background in aiding biopharmaceutical firms through transformative stages, her contributions are expected to align with the company’s ambitions.
With over 20 years in finance, corporate development, and investor relations, Ridloff has held influential positions that have shaped the dynamics of the biopharmaceutical landscape. Before joining Immunic, she served as the Chief Financial Officer of Sionna Therapeutics, and prior to that, was the Executive Vice President and CFO of ACADIA Pharmaceuticals, where she spearheaded a major capital raise initiative. Ridloff has also established a strong track record as the leader of investor relations at Alexion Pharmaceuticals and has experience providing consultancy services to life sciences through her firm, BIOVISIO.
'Joining Immunic's Board at this pivotal stage is an honor,' Ridloff remarked regarding her new role. She highlighted the company's impressive team and its focus on advancing innovative oral therapies that have the potential to make significant impacts on MS treatment protocols. She is keen to contribute to the strategic direction and execution of the company’s roadmap, particularly as it prepares for crucial clinical trials and regulatory submissions.
Immunic is focused on its lead pipeline candidate, vidofludimus calcium (IMU-838), which is currently undergoing crucial testing aimed at addressing cases of relapsing multiple sclerosis. The company expects to unveil top-line data from these Phase 3 studies by the end of 2026, with further plans to initiate an additional Phase 3 trial in progressive forms of MS later in the same year. Initial Phase 2 trials have shown positive results, suggesting a favorable safety profile along with therapeutic potential.
The company emphasizes that vidofludimus calcium combines the neuroprotective effects that may significantly benefit patients with its unique dual action of anti-inflammatory and anti-viral mechanisms. This makes it a promising candidate for therapy options targeting MS, as it selectively inhibits the dihydroorotate dehydrogenase enzyme (DHODH), which plays a role in the disease’s progression.
Alongside Ridloff’s appointment, Immunic is also advancing its development programs, which include other candidates such as IMU-381 and IMU-856. These initiatives are strategically aimed at broadening the company’s therapeutic platform for both neurodegenerative and autoimmune diseases, thereby reinforcing its commitment to improving patient outcomes.
As Immunic heads towards these significant milestones, the industry watches closely, hoping for the breakthroughs that lie ahead—fueled by the insights and leadership Ridloff will bring to this dynamic organization.
Michael W. Bonney, the Chair of Immunic's Board, expressed enthusiasm over this new appointment. 'We are excited to welcome Elena to our Board as we enter an important period for Immunic,' he stated. He emphasized Ridloff’s extensive experience and reputation within the biotech sector, believing her insights will prove invaluable as the company navigates its next chapter.
Mr. Erik Lundgren, CEO of Immunic, added that the company is approaching critical milestones, such as the anticipated top-line data from the Phase 3 ENSURE trials involving vidofludimus calcium, intended for the treatment of relapsing multiple sclerosis (MS). He noted that this period marks a crucial phase in the company’s growth trajectory. With Ridloff's impressive background in aiding biopharmaceutical firms through transformative stages, her contributions are expected to align with the company’s ambitions.
With over 20 years in finance, corporate development, and investor relations, Ridloff has held influential positions that have shaped the dynamics of the biopharmaceutical landscape. Before joining Immunic, she served as the Chief Financial Officer of Sionna Therapeutics, and prior to that, was the Executive Vice President and CFO of ACADIA Pharmaceuticals, where she spearheaded a major capital raise initiative. Ridloff has also established a strong track record as the leader of investor relations at Alexion Pharmaceuticals and has experience providing consultancy services to life sciences through her firm, BIOVISIO.
'Joining Immunic's Board at this pivotal stage is an honor,' Ridloff remarked regarding her new role. She highlighted the company's impressive team and its focus on advancing innovative oral therapies that have the potential to make significant impacts on MS treatment protocols. She is keen to contribute to the strategic direction and execution of the company’s roadmap, particularly as it prepares for crucial clinical trials and regulatory submissions.
Immunic is focused on its lead pipeline candidate, vidofludimus calcium (IMU-838), which is currently undergoing crucial testing aimed at addressing cases of relapsing multiple sclerosis. The company expects to unveil top-line data from these Phase 3 studies by the end of 2026, with further plans to initiate an additional Phase 3 trial in progressive forms of MS later in the same year. Initial Phase 2 trials have shown positive results, suggesting a favorable safety profile along with therapeutic potential.
The company emphasizes that vidofludimus calcium combines the neuroprotective effects that may significantly benefit patients with its unique dual action of anti-inflammatory and anti-viral mechanisms. This makes it a promising candidate for therapy options targeting MS, as it selectively inhibits the dihydroorotate dehydrogenase enzyme (DHODH), which plays a role in the disease’s progression.
Alongside Ridloff’s appointment, Immunic is also advancing its development programs, which include other candidates such as IMU-381 and IMU-856. These initiatives are strategically aimed at broadening the company’s therapeutic platform for both neurodegenerative and autoimmune diseases, thereby reinforcing its commitment to improving patient outcomes.
As Immunic heads towards these significant milestones, the industry watches closely, hoping for the breakthroughs that lie ahead—fueled by the insights and leadership Ridloff will bring to this dynamic organization.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.